These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 19943710

  • 1. Telavancin.
    Lyseng-Williamson KA, Blick SK.
    Drugs; 2009; 69(18):2607-20. PubMed ID: 19943710
    [Abstract] [Full Text] [Related]

  • 2. Telavancin: a review of its use in patients with nosocomial pneumonia.
    Scott LJ.
    Drugs; 2013 Nov; 73(16):1829-39. PubMed ID: 24190596
    [Abstract] [Full Text] [Related]

  • 3. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
    Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, Rahav G, Niederman MS, Kollef MH, Shorr AF, Lee PC, Lentnek AL, Luna CM, Fagon JY, Torres A, Kitt MM, Genter FC, Barriere SL, Friedland HD, Stryjewski ME, ATTAIN Study Group.
    Clin Infect Dis; 2011 Jan 01; 52(1):31-40. PubMed ID: 21148517
    [Abstract] [Full Text] [Related]

  • 4. The role of telavancin in the treatment of MRSA infections in hospital.
    Bassetti M, Mikulska M, Righi E, Nicolini L, Viscoli C.
    Expert Opin Investig Drugs; 2009 Apr 01; 18(4):521-9. PubMed ID: 19335280
    [Abstract] [Full Text] [Related]

  • 5. Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.
    Nannini EC, Corey GR, Stryjewski ME.
    Expert Rev Anti Infect Ther; 2012 Aug 01; 10(8):847-54. PubMed ID: 23030322
    [Abstract] [Full Text] [Related]

  • 6. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
    Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA.
    Drugs; 2010 May 07; 70(7):859-86. PubMed ID: 20426497
    [Abstract] [Full Text] [Related]

  • 7. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.
    Stryjewski ME, Lentnek A, O'Riordan W, Pullman J, Tambyah PA, Miró JM, Fowler VG, Barriere SL, Kitt MM, Corey GR.
    BMC Infect Dis; 2014 May 23; 14():289. PubMed ID: 24884578
    [Abstract] [Full Text] [Related]

  • 8. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
    Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR, Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study.
    Clin Infect Dis; 2008 Jun 01; 46(11):1683-93. PubMed ID: 18444791
    [Abstract] [Full Text] [Related]

  • 9. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.
    Sandrock CE, Shorr AF.
    Clin Infect Dis; 2015 Sep 15; 61 Suppl 2():S79-86. PubMed ID: 26316561
    [Abstract] [Full Text] [Related]

  • 10. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.
    Stryjewski ME, Chu VH, O'Riordan WD, Warren BL, Dunbar LM, Young DM, Vallée M, Fowler VG, Morganroth J, Barriere SL, Kitt MM, Corey GR, FAST 2 Investigator Group.
    Antimicrob Agents Chemother; 2006 Mar 15; 50(3):862-7. PubMed ID: 16495243
    [Abstract] [Full Text] [Related]

  • 11. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
    Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, Fowler VG, Chu VH, Spencer E, Barriere SL, Kitt MM, Cabell CH, Corey GR, FAST Investigator Group.
    Clin Infect Dis; 2005 Jun 01; 40(11):1601-7. PubMed ID: 15889357
    [Abstract] [Full Text] [Related]

  • 12. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.
    Corey GR, Rubinstein E, Stryjewski ME, Bassetti M, Barriere SL.
    Clin Infect Dis; 2015 Mar 01; 60(5):787-96. PubMed ID: 25472944
    [Abstract] [Full Text] [Related]

  • 13. ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections.
    Barriere SL.
    Future Microbiol; 2010 Dec 01; 5(12):1765-73. PubMed ID: 21080861
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections.
    Stryjewski ME, Barriere SL, O'Riordan W, Dunbar LM, Hopkins A, Genter FC, Corey GR.
    J Antimicrob Chemother; 2012 Jun 01; 67(6):1496-502. PubMed ID: 22416054
    [Abstract] [Full Text] [Related]

  • 15. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
    Laohavaleeson S, Kuti JL, Nicolau DP.
    Expert Opin Investig Drugs; 2007 Mar 01; 16(3):347-57. PubMed ID: 17302529
    [Abstract] [Full Text] [Related]

  • 16. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures.
    Wilson SE, O'Riordan W, Hopkins A, Friedland HD, Barriere SL, Kitt MM, ATLAS Investigators.
    Am J Surg; 2009 Jun 01; 197(6):791-6. PubMed ID: 19095213
    [Abstract] [Full Text] [Related]

  • 17. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
    Zhanel GG, Lam A, Schweizer F, Thomson K, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Noreddin AM, Karlowsky JA.
    Am J Clin Dermatol; 2008 Jun 01; 9(4):245-54. PubMed ID: 18572975
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
    Hegde SS, Reyes N, Wiens T, Vanasse N, Skinner R, McCullough J, Kaniga K, Pace J, Thomas R, Shaw JP, Obedencio G, Judice JK.
    Antimicrob Agents Chemother; 2004 Aug 01; 48(8):3043-50. PubMed ID: 15273119
    [Abstract] [Full Text] [Related]

  • 19. Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial.
    Bae IG, Tonthat GT, Stryjewski ME, Rude TH, Reilly LF, Barriere SL, Genter FC, Corey GR, Fowler VG.
    J Clin Microbiol; 2009 Dec 01; 47(12):3952-7. PubMed ID: 19846653
    [Abstract] [Full Text] [Related]

  • 20. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
    Crandon JL, Kuti JL, Nicolau DP.
    Antimicrob Agents Chemother; 2010 Dec 01; 54(12):5115-9. PubMed ID: 20837760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.